News H. Lundbeck A/S

Stocks

HLUN B

DK0061804770

Pharmaceuticals

Market Closed - Nasdaq Copenhagen Other stock markets 08:50:00 15/06/2026 pm IST			5-day change	1st Jan Change
43.24 ^DKK	-1.05%		+0.05%	+0.19%

15/06	H. Lundbeck A/S Presents Preliminary Phase II Part A Data for Asedebart in Cushing's Disease	CI
05/06	H. Lundbeck A/S - Special Call

All News

Mentions Relevance

15/06	Lundbeck presents new Phase II asedebart data in Cushing's disease at ENDO 2026	AQ
15/06	H. Lundbeck A/S Presents Preliminary Phase II Part A Data for Asedebart in Cushing's Disease	CI
10/06	Lundbeck to present new patient data on neuroendocrine and neuroimmunology programs at ENDO 2026	AQ
05/06	H. Lundbeck A/S - Special Call
05/06	Lundbeck reports positive Phase 2b results for migraine candidate	FW
05/06	H. Lundbeck Presents Positive Phase IIb Data For Bocunebart In Migraine Prevention	CI
05/06	Lundbeck presents positive Phase IIb data for bocunebart (Lu AG09222; anti-PACAP mAb) in migraine prevention at the AHS congress	AQ
03/06	Lundbeck Enters Partnership with Cradle for Brain Disorder Therapies	MT
03/06	Lundbeck enters AI partnership with Cradle for drug development	FW
03/06	Lundbeck Partners with Cradle to Discover and Optimize Brain Disorder Treatments	AQ
26/05	Lundbeck Obtains Marketing Permit for Migraine Drug Vyepti in South Korea	MT
26/05	Lundbeck secures South Korean approval for migraine treatment	FW
26/05	Lundbeck receives marketing authorization for Vyepti® (eptinezumab) in South Korea for the preventive treatment of migraine	AQ
26/05	H. Lundbeck A/S Receives Marketing Authorization for Vyepti (Eptinezumab) in South Korea for Preventive Treatment of Migraine	CI
19/05	H Lundbeck A/S : Transcript (Transcript)	PU
18/05	Lundbeck's Asedebart Secures Orphan Drug Designation in Japan	MT
18/05	Lundbeck granted Orphan Drug Designation in Japan for asedebart	FW
18/05	Lundbeck receives orphan drug designation in Japan for asedebart for the treatment of patients with congenital adrenal hyperplasia and Cushing's disease	AQ
13/05	H. Lundbeck A/S, Q1 2026 Earnings Call, May 13, 2026
13/05	H Lundbeck: Strong Q1, but long-term growth uncertainty hovers over valuation
13/05	H Lundbeck A/S : Investor Presentation (Lundbeck InvestorDeck Q1 2026 FINAL)	PU
13/05	Nordea raises Lundbeck price target to DKK 57 (55), reiterates Buy	FW
13/05	DNB Carnegie raises Lundbeck price target to DKK 54 (53), reiterates Buy	FW
12/05	H. Lundbeck A/S Raises Earning Guidance for Full Year of 2026	CI
12/05	H. Lundbeck A/S Reports Earnings Results for the First Quarter Ended March 31, 2026	CI